Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Epidemiologic aspects of uveal melanoma
1988408 citationsKathleen M. Egan, Johanna M. Seddon et al.Survey of Ophthalmologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of D. M. Albert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. M. Albert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. M. Albert more than expected).
This network shows the impact of papers produced by D. M. Albert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. M. Albert. The network helps show where D. M. Albert may publish in the future.
Co-authorship network of co-authors of D. M. Albert
This figure shows the co-authorship network connecting the top 25 collaborators of D. M. Albert.
A scholar is included among the top collaborators of D. M. Albert based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with D. M. Albert. D. M. Albert is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Bertha, G., et al.. (2009). The National Oncology Program. Hematology/Oncology and Stem Cell Therapy. 2(1). 294–298.5 indexed citations
2.
Miller, Paul E., Christian Bueger, Joseph C. Beyer, et al.. (2003). 26-Week Intravitreal Injection Toxicity Study with rhuFab Vegf in Cynomolgus Monkeys with an 8-Week Recovery. Investigative Ophthalmology & Visual Science. 44(13). 3929–3929.3 indexed citations
3.
Bueger, Christian, P. Elliott Miller, Robert A. Leedle, et al.. (2000). Safety evaluation of intravitreal administration of rhuFab VEGF in cynomolgus monkeys for 3 months. 41(4). 14215.1 indexed citations
Araiz, Javier, et al.. (1993). Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy.. PubMed. 34(3). 522–30.77 indexed citations
Elner, Victor M., Roberto Díaz-Rohena, H. Mackenzie Freeman, Felipe I. Tolentino, & D. M. Albert. (1988). Anterior Prolioferative Vitreoretinopathy. Ophthalmology. 95(10). 1349–1357.20 indexed citations
13.
Egan, Kathleen M., Johanna M. Seddon, Robert J. Glynn, Evangelos S. Gragoudas, & D. M. Albert. (1988). Epidemiologic aspects of uveal melanoma. Survey of Ophthalmology. 32(4). 239–251.408 indexed citations breakdown →
Albert, D. M., et al.. (1982). Metastasis in a rabbit choroidal melanoma model.. PubMed. 22(1). 115–8.10 indexed citations
16.
Lubin, Jane R., et al.. (1982). High altitude retinal hemorrhage: a clinical and pathological case report.. PubMed. 14(11). 1071–6.16 indexed citations
17.
Albert, D. M., et al.. (1980). Heterotransplantation of human choroidal melanoma into the athymic "nude" mouse.. PubMed. 19(5). 555–9.13 indexed citations
18.
Dryja, Thaddeus P., et al.. (1980). Light stimulation of iris tyrosinase in vivo.. PubMed. 19(5). 559–62.7 indexed citations
19.
Refojo, Miguel F., et al.. (1979). Sustained release of BCNU for the treatment of intraocular malignancies in animal models.. PubMed. 18(10). 1061–7.8 indexed citations
20.
Zakov, Z. N., et al.. (1979). Vascular basophilia in ocular and orbital tumors.. PubMed. 18(10). 1068–75.4 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.